179057-19-3

Usage

Uses

Used in Pharmaceutical Industry:
(5-phenyl-1H-pyrazol-3-yl)methanol(SALTDATA: FREE) is used as a key intermediate in the synthesis of various drugs and bioactive molecules. Its unique structure and properties contribute to the development of novel pharmaceutical agents with potential therapeutic applications.
Used in Chemical Industry:
In the chemical industry, (5-phenyl-1H-pyrazol-3-yl)methanol(SALTDATA: FREE) serves as a valuable building block in organic synthesis, enabling the creation of a wide range of chemical compounds with diverse applications.
Used in Medicinal Chemistry:
(5-phenyl-1H-pyrazol-3-yl)methanol(SALTDATA: FREE) is used as a compound with potential antimicrobial and antifungal activities. Its presence in the field of medicinal chemistry highlights its importance in the development of new treatments and therapies to combat various infections and diseases.

Upstream product

• 5932-30-9 ethyl 5-phenylpyrazole-3-carboxylate 
• 56426-35-8 methyl 5-phenyl-1H-pyrazole-3-carboxylate 
• 13599-12-7 ethyl 3-phenyl-1H-pyrazole-5-carboxylate 
• 20577-73-5 methyl 4-phenyl-2,4-dioxobutanoate 
• 98-86-2 acetophenone 
• 84907-64-2 4-[(tetrahydro-2H-pyran-2-yl)oxy]-1-phenylbut-2-yn-1-one 
• 98-88-4 benzoyl chloride 
• 493038-47-4 5-phenyl-3-[(tetrahydro-2H-pyran-2-yl)oxy]methylpyrazole 

Downstream Products

• 57204-65-6 3-phenyl-1H-pyrazole-5-carbaldehyde 
• 1448604-40-7 diethyl 2-phenylpyrazolo[1,5-a]pyridin-5-ylphosphonate 
• 755700-32-4 5-(chloromethyl)-3-phenyl-1H-pyrazole 
• 57204-65-6 5-phenyl-1⁽²⁾H-pyrazole-3-carbaldehyde 

Relevant academic research and scientific papers

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

Design, synthesis and anti-HIV evaluation of 5-alkyl- 6-(benzo[d][1,3]dioxol-5-alkyl)-2-mercaptopyrimidin-4(3H)-ones as potent HIV-1 NNRTIs

In order to discover and develop the new HIV-1 NNRTIs, a series of 5-alkyl-6-(benzo[d][1,3]dioxol-5-ylalkyl)-2-mercaptopyrimidin-4(3H)-ones was synthesized and screened for their in vitro cytotoxicity against HIV-1. Most of the compounds we synthetized sh

Bicyclic Pyridinylpyrazoles

Bicyclic pyridinylpyrazoles of the formula (I) in which the symbols have the meanings given in the description and agrochemically active salts thereof and their use for controlling unwanted microorganisms in crop protection and the protection of materials

A novel and efficient approach to pyrazolo[1,5-a]pyridine derivatives via one-pot tandem reaction

An unusual intramolecular condensation of a, α,β-unsaturated esters with aldehydes was discovered and the pyrazolo[1,5-α]pyridine derivatives were conveniently synthesized by this novel tandem reaction under very mild conditions. The reaction mechanism was also proposed.

New flexible synthesis of pyrazoles with different, functionalized substituents at C3 and C5

Syntheses of pyrazoles featuring a functionalized side chain attached to carbon 3 and varying alkyl and aryl substituents attached to carbon 5 are presented. Installation of R = methyl, isopropyl, tert-butyl, adamantyl, or phenyl groups at C5 is reported

Inhibitors of acyl-coA:cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N- (heteroaryl-substituted benzyl)-N'-arylureas

A series of N-alkyl-N-(heteroaryl-substituted benzyl)-N'-arylurea and related derivatives represented by 2 and 3 have been prepared and evaluated for their ability to inhibit acyl-CoA:cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Among these novel compounds, the type 3 series was superior. A pyrazol-3-yl group on the N-benzyl group of this trisubstituted urea (i.e. 3, Ar1 = pyrazol-3- yl) was identified as a heteroaromatic ring providing a good profile of biological activity. As a result of optimization of the combination with the N-alkyl group (R) and N-aryl group (At3), compound 3aq (FR186054) was identified as a new, orally efficacious ACAT inhibitor, which exhibited potent in vitro ACAT inhibitory activity (rabbit intestinal microsomes IC50 = 99 nM) and excellent hypocholesterolemic effects in cholesterol-fed rats, irrespective of administration mode (ED50 = 0.046 mg/kg dosed via the diet, ED50 = 0.44 mg/kg administered by gavage in PEG400 vehicle). Moreover, a toxicological study revealed compound 3aq to be nontoxic to the adrenal glands of dogs when tested at a single dose of 10 mg/kg po.